392 related articles for article (PubMed ID: 38792835)
1. Exploring the Toxin-Mediated Mechanisms in
Pourliotopoulou E; Karampatakis T; Kachrimanidou M
Microorganisms; 2024 May; 12(5):. PubMed ID: 38792835
[No Abstract] [Full Text] [Related]
2. The role of toxins in Clostridium difficile infection.
Chandrasekaran R; Lacy DB
FEMS Microbiol Rev; 2017 Nov; 41(6):723-750. PubMed ID: 29048477
[TBL] [Abstract][Full Text] [Related]
3. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
4. The microbial metabolite urolithin A reduces
Ghosh S; Erickson D; Chua MJ; Collins J; Jala VR
mSystems; 2024 Feb; 9(2):e0125523. PubMed ID: 38193707
[No Abstract] [Full Text] [Related]
5. An Update on
Martínez-Meléndez A; Cruz-López F; Morfin-Otero R; Maldonado-Garza HJ; Garza-González E
Toxins (Basel); 2022 Apr; 14(5):. PubMed ID: 35622552
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis and genotyping of pathogenicity locus in Clostridioides difficile strains isolated from patients in Tehran hospitals during the years 2007-2010.
Azimirad M; Azizi O; Alebouyeh M; Aslani MM; Mousavi SF; Zali MR
Infect Genet Evol; 2019 Jul; 71():205-210. PubMed ID: 30902742
[TBL] [Abstract][Full Text] [Related]
7. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
[TBL] [Abstract][Full Text] [Related]
8. Human intestinal enteroids as a model of
Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
[No Abstract] [Full Text] [Related]
9. Human α-Defensin-5 Efficiently Neutralizes
Korbmacher M; Fischer S; Landenberger M; Papatheodorou P; Aktories K; Barth H
Front Pharmacol; 2020; 11():1204. PubMed ID: 32903430
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of
Raeisi H; Azimirad M; Asadzadeh Aghdaei H; Zarnani AH; Abdolalizadeh J; Yadegar A; Zali MR
Microbiol Spectr; 2023 Sep; 11(5):e0531022. PubMed ID: 37668373
[TBL] [Abstract][Full Text] [Related]
11. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.
Wang S; Heuler J; Wickramage I; Sun X
Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695
[TBL] [Abstract][Full Text] [Related]
12. The Importance of Therapeutically Targeting the Binary Toxin from
Abeyawardhane DL; Godoy-Ruiz R; Adipietro KA; Varney KM; Rustandi RR; Pozharski E; Weber DJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805767
[TBL] [Abstract][Full Text] [Related]
13. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
14. Genomic and phenotypic studies among
Meléndez-Sánchez D; Hernández L; Ares M; Méndez Tenorio A; Flores-Luna L; Torres J; Camorlinga-Ponce M
Microbiol Spectr; 2024 Jun; ():e0394723. PubMed ID: 38864670
[No Abstract] [Full Text] [Related]
15. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
16. Glucosyltransferase-dependent and independent effects of Clostridioides difficile toxins during infection.
Peritore-Galve FC; Shupe JA; Cave RJ; Childress KO; Washington MK; Kuehne SA; Lacy DB
PLoS Pathog; 2022 Feb; 18(2):e1010323. PubMed ID: 35176123
[TBL] [Abstract][Full Text] [Related]
17. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.
Sun X; Hirota SA
Mol Immunol; 2015 Feb; 63(2):193-202. PubMed ID: 25242213
[TBL] [Abstract][Full Text] [Related]
18. An Updated View on the Cellular Uptake and Mode-of-Action of Clostridioides difficile Toxins.
Papatheodorou P; Minton NP; Aktories K; Barth H
Adv Exp Med Biol; 2024; 1435():219-247. PubMed ID: 38175478
[TBL] [Abstract][Full Text] [Related]
19. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
20.
McKee HK; Kajiwara C; Yamaguchi T; Ishii Y; Shimizu N; Ohara A; Tateda K
J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33830910
[No Abstract] [Full Text] [Related]
[Next] [New Search]
